Literature DB >> 21157663

[Subretinal visual implants].

K Stingl1, U Greppmaier, B Wilhelm, E Zrenner.   

Abstract

Visual implants are medical technologies that replace parts of the visual neuronal pathway. The subretinal implant developed by our group is being used in a human trials since 2005 and replaces the function of degenerated photoreceptors by an electronic device in blind patients. The subretinal implant consists of a 70-µm thin microchip with 1500 microphotodiodes each with an amplifier and an electrode with area of 3 mm × 3 mm. The power supply is provided by a subdermal power supply cable. The microchip is implanted under the macula and transforms the light signal into an electrical one, which is referred directly to the bipolar cells. Requirements for a good function of the implant are a preserved function of the inner retina, as well as clear optic media and a good visual acuity in the earlier life. The current technology can mediate a visual field of 10 - 12° and a computed resolution of up to 0.25° visual angle (corresponding to a visual acuity of 63 / 1000 - 80 / 1000) in blind patients. The so far best results from our studies reached a visual acuity of 21 / 1000 in blind retinitis pigmentosa patients. This overview is intended to inform the ophthalmologist about the current state of the technology and help him/her to advise interested patients. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2010        PMID: 21157663     DOI: 10.1055/s-0029-1245830

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  8 in total

1.  Use of the Argus II retinal prosthesis to improve visual guidance of fine hand movements.

Authors:  Michael P Barry; Gislin Dagnelie
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-08-01       Impact factor: 4.799

Review 2.  [What can blind patients see in daily life with the subretinal Alpha IMS implant? Current overview from the clinical trial in Tübingen].

Authors:  K Stingl; K U Bartz-Schmidt; D Besch; F Gekeler; U Greppmaier; G Hörtdörfer; A Koitschev; T Peters; H Sachs; B Wilhelm; E Zrenner
Journal:  Ophthalmologe       Date:  2012-02       Impact factor: 1.059

Review 3.  [Use of nanoparticles in ophthalomology].

Authors:  I Hahn; P Heiduschka; E Endl; N Eter
Journal:  Ophthalmologe       Date:  2011-09       Impact factor: 1.059

4.  The influence of axial length on confocal scanning laser ophthalmoscopy and spectral-domain optical coherence tomography size measurements: a pilot study.

Authors:  T Röck; B Wilhelm; K U Bartz-Schmidt; D Röck
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-23       Impact factor: 3.117

Review 5.  [Visual prostheses].

Authors:  P Walter
Journal:  Ophthalmologe       Date:  2016-02       Impact factor: 1.059

6.  Emotional wellbeing of blind patients in a pilot trial with subretinal implants.

Authors:  Tobias Peters; Stefan Klingberg; Eberhart Zrenner; Barbara Wilhelm
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-11-29       Impact factor: 3.117

7.  Correlation between optical coherence tomography and multifocal electroretinogram findings with visual acuity in retinitis pigmentosa.

Authors:  Marilita M Moschos; Irini P Chatziralli; George Verriopoulos; Aristeides Triglianos; Dimitrios S Ladas; Dimitrios Brouzas
Journal:  Clin Ophthalmol       Date:  2013-10-16

8.  Artificial vision with wirelessly powered subretinal electronic implant alpha-IMS.

Authors:  Katarina Stingl; Karl Ulrich Bartz-Schmidt; Dorothea Besch; Angelika Braun; Anna Bruckmann; Florian Gekeler; Udo Greppmaier; Stephanie Hipp; Gernot Hörtdörfer; Christoph Kernstock; Assen Koitschev; Akos Kusnyerik; Helmut Sachs; Andreas Schatz; Krunoslav T Stingl; Tobias Peters; Barbara Wilhelm; Eberhart Zrenner
Journal:  Proc Biol Sci       Date:  2013-02-20       Impact factor: 5.349

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.